Risk of cancer and subsequent mortality in primary biliary cholangitis: a population-based cohort study of 3,052 patients by Wester, Axel, Schönau, Johanna, Schattenberg, Jörn, Hagström, Hannes

Get full text

NASH limits anti-tumour surveillance in immunotherapy-treated HCC by Pfister, Dominik, Núñez, Nicolás Gonzalo, Govaere, Olivier, Pinter, Matthias, Szydlowska, Marta, Qiu, Mengjie, Deczkowska, Aleksandra, Weiner, Assaf, Müller, Florian, Sinha, Ankit, Friebel, Ekaterina, Engleitner, Thomas, Lenggenhager, Daniela, Moncsek, Anja, Heide, Danijela, Stirm, Kristin, Kosla, Jan, Kotsiliti, Eleni, Leone, Valentina, Dudek, Michael, Yousuf, Suhail, Inverso, Donato, Singh, Indrabahadur, Teijeiro, Ana, Castet, Florian, Montironi, Carla, Haber, Philipp K., Tiniakos, Dina, Bedossa, Pierre, Cockell, Simon, Younes, Ramy, Marra, Fabio, Schattenberg, Jörn M., Allison, Michael, Bugianesi, Elisabetta, Ratziu, Vlad, D’Alessio, Antonio, Personeni, Nicola, Rimassa, Lorenza, Daly, Ann K., Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Peck-Radosavljevic, Markus, Hucke, Florian, Finkelmeier, Fabian, Trojan, Jörg, Schulze, Kornelius, Wege, Henning, Koch, Sandra, Weinmann, Arndt, Bueter, Marco, Rössler, Fabian, Siebenhüner, Alexander, Mallm, Jan-Philipp, Umansky, Viktor, Jugold, Manfred, Luedde, Tom, Schietinger, Andrea, Schirmacher, Peter, Emu, Brinda, Augustin, Hellmut G., Billeter, Adrian, Müller-Stich, Beat, Kikuchi, Hiroto, Duda, Dan G., Waldschmidt, Dirk-Thomas, Rahbari, Nuh, Mei, Henrik E., Schulz, Axel Ronald, Ringelhan, Marc, Malek, Nisar, Spahn, Stephan, Bitzer, Michael, Ruiz de Galarreta, Marina, Lujambio, Amaia, Dufour, Jean-Francois, Marron, Thomas U., Kaseb, Ahmed, Kudo, Masatoshi, Huang, Yi-Hsiang, Djouder, Nabil, Wolter, Katharina, Zender, Lars, Decaens, Thomas, Pinato, David J., Rad, Roland, Mertens, Joachim C., Weber, Achim, Unger, Kristian, Meissner, Felix, Roth, Susanne, Jilkova, Zuzana Macek, Claassen, Manfred, Anstee, Quentin M., Amit, Ido, Knolle, Percy, Becher, Burkhard, Llovet, Josep M., Heikenwalder, Mathias

Get full text

FRI-199 Insulin resistance as an independent predictor of metabolic dysfunction-associated steatohepatitis (MASH) severity: combined data from multiple therapeutic trials including... by Ratziu, Vlad, Schattenberg, Jörn M., Alkhouri, Naim, Noureddin, Mazen, Charlton, Michael, Dubourg, Julie, Harrison, Stephen A.

Get full text

FRI-260 Diagnosed prevalence of cardio-renal diseases, mental health disorders, sleep apnea, cancer, and mortality rates in more than 18, 000 patients with metabolic dysfunction-as... by Schattenberg, Jörn M., Sartini, Claudio, Herrera, Ronald, Raluy, Mireia, Yates, Mark, Younes, Ramy

Get full text

WED-196 Analyses of fibrosis biomarkers PRO-C3 and ELF in resmetirom treated patients from MAESTRO-NASH, a 52 Week NASH/MASH serial liver biopsy study by Anstee, Quentin M., Schattenberg, Jörn M, Taub, Rebecca, Labriola, Dominic, Zhang, Hang, Hennan, Jim

Get full text

WED-197 How many real world patients diagnosed with metabolic dysfunction-associated steatohepatitis meet clinical trial eligibility criteria? Findings from a large cohort study of... by Schattenberg, Jörn M, Sartini, Claudio, Herrera, Ronald, Raluy, Mireia, Yates, Mark, Younes, Ramy

Get full text

TOP-265 Non-invasive predictive markers of resmetirom biopsy response by Loomba, Rohit, Schattenberg, Jörn M, Taub, Rebecca, Labriola, Dominic, Noureddin, Mazen, Ratziu, Vlad, Harrison, Stephen A.

Get full text

SAT-450 Exploring racial, ethnic, and demographics representativeness in MASH clinical trials: combined data from multiple therapeutic trials including more than 10, 000 patients by Schattenberg, Jörn M., Alkhouri, Naim, Noureddin, Mazen, Ratziu, Vlad, Charlton, Michael, Dubourg, Julie, Harrison, Stephen A.

Get full text

TOP-300 Clinical, biological and imaging predictors of advanced fibrosis (F3-F4): combined data frommultiple therapeutic trials including more than 10, 000 patients by Noureddin, Mazen, Alkhouri, Naim, Ratziu, Vlad, Schattenberg, Jörn M, Charlton, Michael, Dubourg, Julie, Harrison, Stephen A.

Get full text

FRI-247 Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10, 000 patients by Harrison, Stephen A., Dubourg, Julie, Ratziu, Vlad, Schattenberg, Jörn M., Alkhouri, Naim, Noureddin, Mazen, Charlton, Michael

Get full text

OS-117 Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial by Schattenberg, Jörn M, Loomba, Rohit, Taub, Rebecca, Labriola, Dominic, Harrison, Stephen A., Noureddin, Mazen

Get full text

FRI-249 Association between uric acid concentration and MASH: combined data from multiple therapeutic trials including more than 10, 000 patients by Harrison, Stephen A., Dubourg, Julie, Ratziu, Vlad, Schattenberg, Jörn M., Alkhouri, Naim, Noureddin, Mazen, Charlton, Michael

Get full text

FRI-235 Causes of death, mortality rates, and the role of sociodemographic risk factors and biomarkers in metabolic dysfunction-associated steatohepatitis mortality in more than 18... by Schattenberg, Jörn M, Sartini, Claudio, Herrera, Ronald, Raluy, Mireia, Yates, Mark, Younes, Ramy

Get full text

SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study by Harrison, Stephen A., Schattenberg, Jörn M., Taub, Rebecca, Labriola, Dominic, Hill, Brandon, Ratziu, Vlad

Get full text

WED-201 Performance of non-invasive tests to diagnose cirrhosis in MASH trials: combined data from multiple therapeutic trials by Alkhouri, Naim, Noureddin, Mazen, Schattenberg, Jörn M, Ratziu, Vlad, Charlton, Michael, Dubourg, Julie, Harrison, Stephen A.

Get full text

WED-202 The 2023 AASLD practice guidance for MASLD does not adequately risk stratify MASLD patients in the context of therapeutic trials by Alkhouri, Naim, Noureddin, Mazen, Schattenberg, Jörn M, Ratziu, Vlad, Charlton, Michael, Dubourg, Julie, Harrison, Stephen A.

Get full text

Referral care paths for non‐alcoholic fatty liver disease—Gearing up for an ever more prevalent and severe liver disease by van Dijk, Anne‐Marieke, Schattenberg, Jörn M., Holleboom, Adriaan G., Tushuizen, Maarten E.

Get full text

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD) by Zimmermann, Tim, Hoppe-Lotichius, Maria, Tripkovic, Vuk, Barreiros, Ana P, Wehler, Thomas C, Zimmermann, Anca, Schattenberg, Jörn M, Heise, Michael, Biesterfeld, Stefan, Galle, Peter R, Otto, Gerd, Schuchmann, Marcus

Get full text

THU-437 - Impairment of health-related quality of life among people with type 2 diabetes and advanced fibrosis by Michel, Maurice, Doll, Michelle, Armandi, Angelo, Labenz, Christian, Galle, Peter, Schattenberg, Jörn

Get full text

Impairment of health-related quality of life among people with type 2 diabetes and advanced fibrosis by Michel, Maurice, Doll, Michelle, Armandi, Angelo, Labenz, Christian, Galle, Peter, Schattenberg, Jörn

Get full text